All In Biotech

Free tool

FAERS Monitor: Monjuvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761163 or its brand name (Monjuvi, Tafasitamab-Cxix). Reports on generic versions are filed under their own applications.

Reports

906

Serious

665

73% of reports

Hospitalization

144

Death reported

131

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression239
  • off label use168
  • lymphoma165
  • death66
  • drug ineffective47
  • diffuse large b-cell lymphoma42
  • neutropenia39
  • blood lactate dehydrogenase increased38
  • malignant neoplasm progression38
  • covid-1930
  • polyneuropathy29
  • diarrhoea28
  • pyrexia28
  • product use issue27
  • cytopenia26

Reports by year received

View as table
YearReports
202012
202193
2022179
2023380
2024135
202565
202642

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,253 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lymphomaSignal165250.6218.140,371
diffuse large b-cell lymphomaSignal42127.294.65,108
polyneuropathySignal2956.439.41,520
blood lactate dehydrogenase increasedSignal3855.840.81,987
cytopeniaSignal2649.433.81,183
disease progressionSignal23947.042.110,749
malignant neoplasm progressionSignal388.66.3249
neutropeniaSignal396.74.9183
off label useSignal1684.53.9466
covid-19Signal304.02.864
product use issueSignal273.32.342
pyrexia281.91.311
death661.81.423
diarrhoea281.00.70
drug ineffective470.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.